KR960701648A - Pdgf와 비타민 d를 함유하는 조골세포 성장 자극 조성물(oesteoblast growth stimulating compostion containing pdgf and vitamind) - Google Patents

Pdgf와 비타민 d를 함유하는 조골세포 성장 자극 조성물(oesteoblast growth stimulating compostion containing pdgf and vitamind)

Info

Publication number
KR960701648A
KR960701648A KR1019950704221A KR19950704221A KR960701648A KR 960701648 A KR960701648 A KR 960701648A KR 1019950704221 A KR1019950704221 A KR 1019950704221A KR 19950704221 A KR19950704221 A KR 19950704221A KR 960701648 A KR960701648 A KR 960701648A
Authority
KR
South Korea
Prior art keywords
pdgf
composition
vitamin
growth
ratio
Prior art date
Application number
KR1019950704221A
Other languages
English (en)
Inventor
이. 모어 에마
Original Assignee
마크 제이. 머레이
지모제네틱스 인코퍼레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 마크 제이. 머레이, 지모제네틱스 인코퍼레이티드 filed Critical 마크 제이. 머레이
Publication of KR960701648A publication Critical patent/KR960701648A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0654—Osteocytes, Osteoblasts, Odontocytes; Bones, Teeth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/38—Vitamins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/135—Platelet-derived growth factor [PDGF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

조골세포의 성장을 자극하기 위한 방법과 조성물이 개시된다. 소판 유도 성장인자와 비타민 D로 이루어진 조성물은 그것의 성장을 시험관내 조골세포의 성장을 촉진하거나 생체내 골 결함의 치료를 촉진하는데 사용될 수 있다.

Description

PDGF와 비타민 D를 함유하는 조골세포 성장 자극 조성물(OESTEOBLAST GROWTH STIMULATING COMPOSTION CONTAINING PDGF AND VITAMIND)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (21)

  1. 조골세포의 성장을 자극하는 방법에 있어서, 조골세포 성장을 자극하기 위하여 소판-유도 성장 인자(PDGF)를 비타민 D와 조합하여 이루어진 조성물을 세포에 적용하는 것으로 이루어지는 것을 특징으로 하는 방법.
  2. 제1항에 있어서, 조성물은 필수적으로 PDGF와 A 사슬이 없는 것을 특징으로 하는 방법.
  3. 제1항에 있어서, 조성물이 재조합 PDGF-BB로 이루어지는 것을 특징으로 하는 방법.
  4. 제1항에 있어서, 조골세포가 시험관내 성장하는 것을 특징으로 하는 방법.
  5. 제4항에 있어서, 상기 조성물내 PDGF의 농도가 1ng/ml 내지 100ng/ml인 것을 특징으로 하는 방법.
  6. 제4항에 있어서, 상기 조성물내 PDGF의 농도가 5ng/ml 내지 40ng/ml인 것을 특징으로 하는 방법.
  7. 제1항에 있어서, 상기 조성물내 PDGF:비타민 D의 비가 6:1 내지 6:500인 것을 특징으로 하는 방법.
  8. 제1항에 있어서, 상기 조성물내 PDGF:비타민 D의 비가 6:10 내지 6:100인 것을 특징으로 하는 방법.
  9. 환자내의 골성장을 자극하는 방법에 있어서, 상기 환자에게 PDGF 및 비타민 D로 이루어진 조성물을 유효량 투여하는 것으로 이루어지는 것을 특징으로 하는 방법.
  10. 제9항에 있어서, 비타민 D가 9,10-세코콜레스타-5,7,10[19]-트리엔-3-올 또는 1α, 25-디히드록시콜레칼시페롤인 것을 특징으로 하는 방법.
  11. 제9항에 있어서, 조성물이 골상처 또는 손상에 국소적으로 전달되는 것을 특징으로 하는 방법.
  12. 제9항에 있어서, 상기 조성물내 PDGF:비타민 D의 비가 6:1 내지 6:500인 것을 특징으로 하는 방법.
  13. 제9항에 있어서, 상기 조성물내 PDGF:비타민 D의 비가 6:10 내지 6:100인 것을 특징으로 하는 방법.
  14. 조골세포의 성장을 자극하는 방법에 있어서, 상기 세포를 PDGF 및 비타민 D로 이루어지는 조성물의 유효량 존재하에서 배양되고, 상기 조성물의 필수적으로 PDGF의 A 사슬이 없는 것을 특징으로 하는 방법.
  15. 약학적으로 허용가능한 담체내에 소판-유도 성장 인자와 비타민 D로 이루어지는 것을 특징으로 하는 약학적 조성물.
  16. 제15항에 있어서, 비타민 D가 9,10-세코클레스타-5.7,10[19]-트리엔-3-올 또는 1α, 25-디히드록시콜레칼시페롤인 것을 특징으로 하는 약학적 조성물.
  17. 제16항에 있어서, 상기 조성물내 PDGF의 농도가 10㎍/ml 내지 500㎍/ml인 것을 특징으로 하는 약학적 조성물.
  18. 제16항에 있어서, PDGF:비타민 D의 비가 6:1 내지 6:500인 것을 특징으로 하는 약학적 조성물.
  19. 제16항에 있어서, PDGF:비타민 D의 비가 6:10 내지 6:100인 것을 특징으로 하는 약학적 조성물.
  20. 제15항에 있어서, 조성물이 필수적으로 PDGF A사슬이 없는 것을 특징으로 하는 약학적 조성물.
  21. 골성장 자극을 위한 약제의 제조에서 소판-유도 성장 인자와 비타민 D의 사용.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019950704221A 1993-03-29 1994-03-29 Pdgf와 비타민 d를 함유하는 조골세포 성장 자극 조성물(oesteoblast growth stimulating compostion containing pdgf and vitamind) KR960701648A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3832593A 1993-03-29 1993-03-29
US08/038,325 1993-03-29
PCT/US1994/003331 WO1994022463A1 (en) 1993-03-29 1994-03-29 Oesteoblast growth stimulating compostion containing pdgf and vitamin d

Publications (1)

Publication Number Publication Date
KR960701648A true KR960701648A (ko) 1996-03-28

Family

ID=21899306

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019950704221A KR960701648A (ko) 1993-03-29 1994-03-29 Pdgf와 비타민 d를 함유하는 조골세포 성장 자극 조성물(oesteoblast growth stimulating compostion containing pdgf and vitamind)

Country Status (14)

Country Link
US (1) US5533836A (ko)
EP (1) EP0691849B1 (ko)
JP (1) JP3699111B2 (ko)
KR (1) KR960701648A (ko)
CN (1) CN1104257C (ko)
AT (1) ATE180674T1 (ko)
AU (1) AU681879B2 (ko)
CA (1) CA2159449C (ko)
DE (1) DE69418865T2 (ko)
DK (1) DK0691849T3 (ko)
ES (1) ES2132399T3 (ko)
GR (1) GR3030402T3 (ko)
RU (1) RU2140282C1 (ko)
WO (1) WO1994022463A1 (ko)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5700289A (en) * 1995-10-20 1997-12-23 North Shore University Hospital Research Corporation Tissue-engineered bone repair using cultured periosteal cells
BR9711805A (pt) 1996-06-20 2002-01-15 Regents The Univesity Of Texas Compostos e métodos para providenciar preparações farmacologicamente ativas e uso dos mesmos
US20030129194A1 (en) * 1997-02-13 2003-07-10 Bone Care International, Inc. Targeted therapeutic delivery of vitamin D compounds
US6042855A (en) * 1997-06-27 2000-03-28 United States Of America (Usda) Use of vitamin D, its metabolites and analogs to improve tenderness of meat and meat products
WO1999033415A1 (en) * 1997-12-31 1999-07-08 Depuy Orthopaedics, Inc. Osteopontin-based compositions for enhancing bone repair
US6551355B1 (en) 1998-08-14 2003-04-22 Cambridge Scientific, Inc. Tissue transplant coated with biocompatible biodegradable polymer
US6663870B2 (en) * 1998-12-07 2003-12-16 Zymogenetics, Inc. Methods for promoting growth of bone using zvegf3
US6468543B1 (en) 1999-05-03 2002-10-22 Zymogenetics, Inc. Methods for promoting growth of bone using ZVEGF4
WO2001032197A2 (en) * 1999-11-02 2001-05-10 Eli Lilly And Company Methods of using lp8, a pdgf-related protein, to treat musculoskeletal disorders
US7473678B2 (en) 2004-10-14 2009-01-06 Biomimetic Therapeutics, Inc. Platelet-derived growth factor compositions and methods of use thereof
NZ571113A (en) * 2005-11-17 2012-02-24 Biomimetic Therapeutics Inc Maxillofacial bone augmentation using rhpdgf-bb and a biocompatible matrix
EP2311505B1 (en) 2006-02-09 2013-11-06 BioMimetic Therapeutics, LLC Compositions and methods for treating bone
EP2049145B1 (en) 2006-06-30 2018-03-14 BioMimetic Therapeutics, LLC Pdgf-biomatrix compositions and methods for treating rotator cuff injuries
US9161967B2 (en) 2006-06-30 2015-10-20 Biomimetic Therapeutics, Llc Compositions and methods for treating the vertebral column
CA2668189C (en) 2006-11-03 2016-01-26 Biomimetic Therapeutics, Inc. Compositions and methods for arthrodetic procedures comprising a solution of platelet derived growth factor (pdgf) incorporated in a biocompatible matrix
RU2010137106A (ru) 2008-02-07 2012-03-20 Байомайметик Терапьютикс, Инк. (Us) Композиции и способы для дистракциионного остеогенеза
WO2009135905A2 (en) * 2008-05-07 2009-11-12 Bone Therapeutics S.A. Novel mesenchymal stem cells and bone-forming cells
US20110142810A1 (en) * 2008-08-19 2011-06-16 Osaka University Cell preparation for bone tissue regeneration
JP5816553B2 (ja) 2008-09-09 2015-11-18 バイオミメティック セラピューティクス， エルエルシー 腱または靭帯の傷害を処置するための血小板由来成長因子組成物および方法
WO2011103598A1 (en) 2010-02-22 2011-08-25 Biomimetic Therapeutics, Inc. Platelet-derived growth factor compositions and methods for the treatment of tendinopathies
RU2014134534A (ru) * 2012-02-01 2016-03-20 Орган Текнолоджиз, Инк. Зубной имплантат и способ его изготовления
WO2016061219A1 (en) 2014-10-14 2016-04-21 Samuel Lynch Compositions for treating wounds

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4264512A (en) * 1975-09-29 1981-04-28 The Regents Of The University Of California 3-Deoxy-1α-hydroxy- and 3-deoxy-1α,25-dihydroxycholecalciferol and processes for the preparation thereof
US4861757A (en) * 1986-11-14 1989-08-29 Institute Of Molecular Biology Wound healing and bone regeneration using PDGF and IGF-I
US5124316A (en) * 1986-11-14 1992-06-23 President And Fellows Of Harvard College Method for periodontal regeneration
US4833125A (en) * 1986-12-05 1989-05-23 The General Hospital Corporation Method of increasing bone mass
US5254538A (en) * 1989-10-04 1993-10-19 Trustees Of Boston University Method of treating periodontal disease
CA2110410C (en) * 1991-06-05 1997-04-15 The Procter & Gamble Company Therapeutic compositions for osteoinduction
US5129691A (en) * 1991-08-20 1992-07-14 Mcfarlen Jonn Gate latch control device

Also Published As

Publication number Publication date
WO1994022463A1 (en) 1994-10-13
CN1121693A (zh) 1996-05-01
CA2159449A1 (en) 1994-10-13
ES2132399T3 (es) 1999-08-16
DE69418865D1 (de) 1999-07-08
US5533836A (en) 1996-07-09
JPH08508499A (ja) 1996-09-10
DE69418865T2 (de) 2000-02-17
GR3030402T3 (en) 1999-09-30
DK0691849T3 (da) 1999-12-13
JP3699111B2 (ja) 2005-09-28
CN1104257C (zh) 2003-04-02
AU6417194A (en) 1994-10-24
RU2140282C1 (ru) 1999-10-27
EP0691849A1 (en) 1996-01-17
ATE180674T1 (de) 1999-06-15
AU681879B2 (en) 1997-09-11
CA2159449C (en) 1999-09-14
EP0691849B1 (en) 1999-06-02

Similar Documents

Publication Publication Date Title
KR960701648A (ko) Pdgf와 비타민 d를 함유하는 조골세포 성장 자극 조성물(oesteoblast growth stimulating compostion containing pdgf and vitamind)
CA2106073C (en) Composition for promoting tissue repair and regeneration
Gerstein et al. Wound healing and aging
EP1545565A4 (en) METHODS AND COMPOSITIONS FOR TISSUE REGENERATION
IL77096A (en) Pharmaceutical compositions for enhancing wound healing comprising angiogene and growth factors
CA2373302A1 (en) Conditioned cell culture medium compositions and methods of use
RU95119807A (ru) Композиция, стимулирующая рост остеобластов, содержащая фрпт и витамин d
DE69433723D1 (de) Verfahren für die in-vivo-verabreichung von biologischen substanzen und hierfür verwendbare zusammensetzungen
PT977564E (pt) Forscolina para promocao da massa corporal magra
FI971420A (fi) Menetelmä diabetes mellituksen hoitamiseksi KGF:ää käyttämällä
CA2105997A1 (en) Method of inhibiting padgem-mediated interactions using an inhibitor comprising a 2,6 sialic acid component
BR9611571A (pt) Composição farmacêutica estável composição farmacêutica kit para administração de ngf e método de aumento da estabilidade de ngf
US6174541B1 (en) Skin aging and wound treatment using cell migration agents
JPH0570365A (ja) 繊維芽細胞増殖因子およびアスコルビン酸含有創傷治癒性組成物類
CA2225898A1 (en) Enhancing keratinocyte migration and proliferation
ES2118726T3 (es) Factor de crecimiento epidermal como medicamento para la restauracion de neuronas de la substantia nigra en el tratamiento de trastornos neurodegenerativos.
ATE285787T1 (de) Antarticine-nf3 zur behandlung und reepithelialisierung von wunden
NO933742L (no) Humant, benavledet, insulinlignende vekstfaktorbindingsprotein
DE69816808D1 (de) Somatostatin agoniste zur reduzierung von körpergewicht
ATE372785T1 (de) Verfahren zur verabreichung von arzneimitteln mit bindungsaffinität zum plasmaprotein und verwendung der zusammensetzung in dem verfahren
JPH07316066A (ja) 創傷治癒剤
ATE258804T1 (de) Verfahren zur verabreichung von wachstumsfaktoren
KR900017599A (ko) 종양 치료용 약학 조성물
UA5743C2 (uk) Препарат тканинних біологічно активних речовин, який має регенаторну дію, та спосіб його одержання
MD1135G2 (ro) Metodă de tratament al afecţiunilor parodonţiului

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application